Personalized prescribing
Pharmacogenomics and Pharmacogenomic Testing
Genetic testing that helps clinicians predict how you are likely to respond to psychiatric medications — before months of trial and error.
About this program
Pharmacogenomics
Pharmacogenomics is the study of how a person’s genetic makeup influences their response to medications. Pharmacogenomic testing analyzes genetic variations that affect drug metabolism, letting clinicians tailor medication selection and dosing to each patient — improving the odds a medication works while reducing the risk of adverse effects.
Prescribing for mental health has historically been trial and error: try a medication, wait weeks, adjust, repeat. That approach can mean long stretches of ineffective treatment and discouraging side effects. Testing does not replace clinical judgment, but it gives prescribers a molecular starting point instead of a guess.
Ambrosia Behavioral Health integrates pharmacogenomic testing into its clinical practice. Results are reviewed with each patient, so the reasoning behind a medication choice is shared — not handed down.
How pharmacogenomic testing works
Sample collection
Testing may be recommended based on medical history, family background, and the current medication regimen. A blood draw, saliva sample, or cheek swab provides the DNA.
Genetic analysis
Laboratory techniques identify variants that influence drug metabolism — for example, in genes such as CYP2D6 and CYP2C19 of the cytochrome P450 family.
Interpretation
Results are read against clinical guidelines and classified into actionable categories: likely to benefit, needs an adjusted dose, or should avoid a particular drug.
Discussion
Findings are explained clearly, with genetic counseling available, so patients understand what their profile means for their treatment options.
What the results can change
Genetic variations affect how rapidly a drug is metabolized, which can lead to underdosing or toxic reactions on a standard prescription. Knowing a patient’s profile lets clinicians choose medications more likely to be effective from the outset, adjust doses to reach therapeutic goals, and avoid drugs that pose a higher risk of adverse reactions.
That matters most in mental health, where side effects are a leading reason people stop taking medications. Reducing the trial-and-error period shortens the time to an effective treatment, supports adherence, and builds a more collaborative relationship between patient and prescriber.
Who benefits most from testing
Treatment-resistant conditions
People with depression, bipolar disorder, or schizophrenia who have cycled through medications without adequate response, where genetic insight can shorten the search.
Multiple medications or comorbidities
People managing psychiatric medication alongside conditions like diabetes or heart disease, where gene–drug interactions across the full regimen matter.
A history of adverse reactions
People whose past medications caused distressing side effects — genetic polymorphisms can predispose someone to those reactions, and testing helps avoid repeating them.
An honest limitation
Genetics is one component of drug response, not the whole picture. Environment, lifestyle, and co-occurring conditions all shape how a medication works, so pharmacogenomic results are part of a broader, integrative treatment plan rather than a standalone directive. Prescribing medication without the evidence-based therapy that should accompany it is an incomplete approach — here, testing informs a plan that always includes the therapeutic work.
Ready to talk with admissions?
Admissions is available 24/7 to answer questions about mental health and substance use treatment options.